---
layout: post
title: New Drug Approvals 2011 - Pt. XXX - Aflibercept (EyleaTM)
date: '2011-11-21T10:38:00.020Z'
author: Patricia
tags:
- 2011 New Drugs
modified_time: '2011-11-22T11:14:13.103Z'
thumbnail: http://2.bp.blogspot.com/-7YWz4j00aNw/TsotmdPoYOI/AAAAAAAAAoQ/f-DGdtbr_zw/s72-c/aflibercept_pict.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8029441306623109613
blogger_orig_url: http://chembl.blogspot.com/2011/11/new-drug-approvals-2011-pt-xxx.html
---

<div style="text-align: center;">
<br />
<img alt="" border="0" id="BLOGGER_PHOTO_ID_5677400418962399458" src="http://2.bp.blogspot.com/-7YWz4j00aNw/TsotmdPoYOI/AAAAAAAAAoQ/f-DGdtbr_zw/s400/aflibercept_pict.jpg" style="display: block; height: 266px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: center; width: 400px;" /></div>
<div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,0" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div style="text-align: center;">
<div style="text-align: center;">
<b>ATC code (partial): <a href="http://www.whocc.no/atc_ddd_index/?code=S01LA">S01LA</a></b><br />
<br /></div>
</div>
</div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">
On November 18th 2011, the FDA approved Aflibercept (trade name: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=eylea">Eylea</a>; Research Code: AVE-0005, &nbsp;also known as VEGF Trap), a recombinant fusion protein indicated for the treatment of patients with neovascular (wet) <a href="http://en.wikipedia.org/wiki/Wet_macular_degeneration">age-related macular degeneration (AMD)</a>.</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br /></span></span></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">
</span></span></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">AMD is an eye condition which usually occurs in older patients and affects the macula area of the retina, causing loss of vision and eventually blindness. In particular, wet AMD is characterised by an abnormal growth of new blood vessels (<a href="http://en.wikipedia.org/wiki/Choroidal_neovascularization">neovascularisation</a>) behind the retina. This originates from an abnormal activation of angiogenesis, by the <a href="http://en.wikipedia.org/wiki/VEGF-A">vascular endothelial growth factor-A</a> (VEGF-A; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1783">CHEMBL1783</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/P15692">P15692</a>) and the <a href="http://en.wikipedia.org/wiki/Placental_growth_factor">placenta growth factor</a> (PlGF; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1697671">CHEMBL1697671</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/P49763">P49763</a>), of the <a href="http://en.wikipedia.org/wiki/VEGF_receptors">vascular endothelial growth factor receptors</a> VEGFR-1 (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL1868">CHEMBL1868</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/P17948">P17948</a>) and VEGFR-2 (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL279">CHEMBL279</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/P35968">P35968</a>), two receptor tyrosine kinases present on the surface of endothelial cells. This leads</span></span> to abnormal increased permeability, scarring and possibly to the loss of fine-resolution central vision. Aflibercept acts as a soluble 'decoy' receptor that binds VEGF-A and PlGF and thereby inhibits the binding and activation of the VEGFR-1 and VEGFR-2 receptors.<br />
<br /></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">
</span></span></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">
</span></span></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5677410749026050210" src="http://1.bp.blogspot.com/-jdvmdTUoQ2E/Tso2_vuuoKI/AAAAAAAAAoo/jUwknN_v_6Y/s200/VEGF_aflibercept.gif" style="cursor: hand; cursor: pointer; display: block; height: 200px; margin: 0px auto 10px; text-align: center; width: 183px;" /></span></span></div>
<div style="text-align: left;">
</div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Aflibercept is a recombinant fusion protein that incorporates portions of </span></span>extracellular domains of the <span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">human VEGFR-1 (containing Ig-like C2-type 2 domain fragment; Uniprot: <a href="http://www.uniprot.org/blast/?about=P17948[151-214]">P17948|151-214|</a>) and VEGFR-2 (</span></span>containing Ig-like C2-type 3 domain fragment; Uniprot: <a href="http://www.uniprot.org/blast/?about=P35968[224-320]">P35968|224-320|</a>) fused to the Fc portion of human <a href="http://en.wikipedia.org/wiki/IgG">immunoglobulin G1 (IgG1)</a>. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kDa (115 kDa with glycosylation).<br />
<br /></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion">
</span><br />
<pre><span class="reflink plainlinks nourlexpansion">&gt;Aflibercept
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
YTQKSLSLSP G
</span></pre>
<span class="reflink plainlinks nourlexpansion">

<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br /></span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Other therapies to treat AMD are available on the market and these include Verteporfin (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1200573">CHEMBL1200573</a>; approved in 2000; trade name Visudyne), </span></span>Pegaptanib sodium (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1201421">CHEMBL1201421</a>; approved in 2004; trade name Macugen) and <span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Ranibizumab (ChEMBL: </span></span><a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1201825">CHEMBL1201825</a>; approved on 2006; trade name Lucentis).</span></div>
<div style="text-align: left;">
</div>
<div style="text-align: left;">
<br />
Aflibercept recommended dosage is 2 mg administrated by <i>intravitreal</i> (into the eye cavity) injection every 4 weeks for the first 12 weeks, followed by 2 mg via intravitreal injection once every 8 weeks.<br />
<br /></div>
<div style="text-align: left;">
Following intravitreal administration of 2 mg per eye, a fraction of the administrated dose binds to the endogenous VEGF in the eye to form the inactive Aflibercept:VEGF complex. Once absorbed into the systemic circulation, Aflibercept presents in the plasma as the free unbound Aflibercept and predominantly as the inactive Aflibercept:VEGF complex. Aflibercept has a volume of distribution (Vd) of 6 L and a terminal elimination half-life (t1/2) of 5 to 6 days after <i>iv</i> administration of doses of 2 to 4 mg.kg-1 of Aflibercept. Aflibercept undergoes elimination through both target-mediated disposition <i>via</i> binding to free endogenous VEGF and metabolism <i>via</i> proteolysis.<br />
<br />
The full prescribing information for Eylea can be found&nbsp;<a href="http://www.regeneron.com/EYLEA-fpi.pdf">here</a>.<br />
<br /></div>
<div style="text-align: left;">
</div>
<div style="text-align: left;">
The license holder is <a href="http://www.regeneron.com/">Regeneron Pharmaceuticals, Inc.</a> and the product website is <a href="http://www.eylea.com/">www.eylea.com</a>.</div>